双侧肾癌伴下腔静脉瘤栓术后转移1例并文献复习
One Case of Postoperative Metastasis of Bilateral Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus and Literature Review
摘要: 肾癌是泌尿系统常见的恶性肿瘤,近年来发病率呈上升趋势,且发病年龄越来越年轻,男性发病率显著高于女性,发病原因与代谢、吸烟、遗传及环境等因素关联密切。肾细胞癌是最常见的肾癌类型,约占肾恶性肿瘤的90%,而其中又以肾透明细胞癌最常见。手术是肾癌的主要治疗方式,局限性肾癌经手术治疗可取得较好疗效,但仍有部分患者会发生术后转移。转移性肾癌通常需要全身系统治疗,目前的治疗方案主要是靶向治疗、免疫治疗及靶免联合治疗。本文通过回顾性分析1例双侧肾细胞癌并下腔静脉瘤栓术后转移患者的临床资料,包括病史、影像学检查、手术治疗及术后随访情况,对其诊疗方案进行综合分析。并结合相关文献复习,为临床治疗此类疾病提供参考。
Abstract: Renal cancer is a common malignant tumor of the urinary system. In recent years, its incidence has been on the rise, and the age of onset has been getting younger. The incidence rate in men is significantly higher than that in women. Its causes are closely related to factors such as metabolism, smoking, genetics, and the environment. Renal cell carcinoma is the most common type of renal cancer, accounting for more than 90% of renal cancers, among which renal clear cell carcinoma is the most prevalent. Surgery is the main treatment method for renal cancer. For localized renal cancer, surgical treatment can generally achieve good therapeutic effects. However, some patients may still experience postoperative metastasis. Metastatic renal cancer generally requires systemic treatment. The current treatment regimens mainly include targeted therapy, immunotherapy, and the combination of targeted and immunotherapy. This article conducts a retrospective analysis of the clinical data of a patient with postoperative metastasis of bilateral renal cell carcinoma and inferior vena cava tumor thrombus, covering aspects such as medical history, imaging examinations, surgical treatment, and postoperative follow-up, and carries out a comprehensive analysis of the diagnosis and treatment plan. Meanwhile, by reviewing the relevant literature, it provides a reference for the clinical treatment of such diseases.
文章引用:丁宁, 于芹超. 双侧肾癌伴下腔静脉瘤栓术后转移1例并文献复习[J]. 临床医学进展, 2025, 15(5): 1834-1840. https://doi.org/10.12677/acm.2025.1551564

参考文献

[1] Jóźwik-Plebanek, K., Saracyn, M., Kołodziej, M., Kamińska, O., Durma, A.D., Mądra, W., et al. (2024) Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review. Pharmaceuticals, 17, 1721. [Google Scholar] [CrossRef] [PubMed]
[2] Padala, S.A., Barsouk, A., Thandra, K.C., Saginala, K., Mohammed, A., Vakiti, A., et al. (2020) Epidemiology of Renal Cell Carcinoma. World Journal of Oncology, 11, 79-87. [Google Scholar] [CrossRef] [PubMed]
[3] Knežević, N., Zekulić, T., Kuliš, T., Penezić, L., Hudolin, T., Čikić, B., et al. (2023) Trends in Surgical Management of Renal Neoplasms: Single Center Results in the Last Decade. Acta Clinica Croatica, 62, 53-59.
[4] Siemer, S., Uder, M., Zell, A., Pönicke, C., Humke, U., Ziegler, M., et al. (2001) Der bilaterale Nierentumor. Der Urologe A, 40, 114-120. [Google Scholar] [CrossRef] [PubMed]
[5] Rothman, J., Crispen, P.L., Wong, Y., Al-Saleem, T., Fox, E. and Uzzo, R.G. (2008) Pathologic Concordance of Sporadic Synchronous Bilateral Renal Masses. Urology, 72, 138-142. [Google Scholar] [CrossRef] [PubMed]
[6] Kim, J.K., Kim, H., Lee, H., Oh, J.J., Lee, S., Hong, S.K., et al. (2021) Evaluation of Functional Outcome of Bilateral Kidney Tumors after Sequential Surgery. BMC Cancer, 21, Article No. 592. [Google Scholar] [CrossRef] [PubMed]
[7] Deng, R., Qiu, J., Shang, J., Yu, C., Tian, P., Zhao, Z., et al. (2024) The Long-Term Survival Outcome of Sporadic Bilateral Renal Cell Carcinoma and Optimization of Surgical Treatment: A Large-Scale Population-Based Cohort Study. Clinical and Experimental Medicine, 25, Article No. 20. [Google Scholar] [CrossRef] [PubMed]
[8] Ohba, K., Mitsunari, K., Nakanishi, H., Yasuda, T., Nakamura, Y., Matsuo, T., et al. (2023) Initial Experience in Robot-Associated Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy. Translational Cancer Research, 12, 3425-3431. [Google Scholar] [CrossRef] [PubMed]
[9] Gu, L., Ma, X., Gao, Y., Li, H., Li, X., Chen, L., et al. (2017) Robotic versus Open Level I-II Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis. Journal of Urology, 198, 1241-1246. [Google Scholar] [CrossRef] [PubMed]
[10] Chen, J., Liu, Z., Peng, R., Liu, Y., Zhang, H., Wang, G., et al. (2024) Neoadjuvant Stereotactic Ablative Body Radiotherapy Combined with Surgical Treatment for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Prospective Pilot Study. BMC Urology, 24, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
[11] Gudapati, P. and Abouamara, M. (2022) Clear Cell Renal Cell Carcinoma with Stage IV Cavoatrial Tumour Thrombus Extension and Rapid Metastatic Reoccurrence Postsurgical Treatment with Review of Current Treatment Strategies. BMJ Case Reports, 15, e248156. [Google Scholar] [CrossRef] [PubMed]
[12] 宿佳琦, 张海梁. 局部进展期肾癌综合治疗研究进展[J]. 肿瘤防治研究, 2023, 50(6): 556-561.
[13] Dudani, S., de Velasco, G., Wells, J.C., Gan, C.L., Donskov, F., Porta, C., et al. (2021) Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival. JAMA Network Open, 4, e2021869. [Google Scholar] [CrossRef] [PubMed]
[14] Ferrel, E., Roehrig, A., Kaya, E., Carlson, J., Ling, B., Wagner, A., et al. (2016) Retrospective Study of Metastatic Melanoma and Renal Cell Carcinoma to the Brain with Multivariate Analysis of Prognostic Pre-Treatment Clinical Factors. International Journal of Molecular Sciences, 17, Article 400. [Google Scholar] [CrossRef] [PubMed]
[15] Guillaume, Z., Auvray, M., Vano, Y., Oudard, S., Helley, D. and Mauge, L. (2022) Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. Cancers, 14, Article 6167. [Google Scholar] [CrossRef] [PubMed]
[16] Jo, J.K., Seo, S.I., Kang, M., Chung, J., Kwak, C., Hong, S., et al. (2024) Optimal Sequential Therapy Using Tyrosine Kinase Inhibitors as the First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma: A Nationwide Multicenter Study. Asian Journal of Urology, 11, 450-459. [Google Scholar] [CrossRef] [PubMed]
[17] Xu, W., Atkins, M.B. and McDermott, D.F. (2020) Checkpoint Inhibitor Immunotherapy in Kidney Cancer. Nature Reviews Urology, 17, 137-150. [Google Scholar] [CrossRef] [PubMed]
[18] Chamoto, K., Hatae, R. and Honjo, T. (2020) Current Issues and Perspectives in PD-1 Blockade Cancer Immunotherapy. International Journal of Clinical Oncology, 25, 790-800. [Google Scholar] [CrossRef] [PubMed]
[19] Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science, 359, 1350-1355. [Google Scholar] [CrossRef] [PubMed]
[20] Meng, L., Collier, K.A., Wang, P., Li, Z., Monk, P., Mortazavi, A., et al. (2023) Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells, 13, Article 34. [Google Scholar] [CrossRef] [PubMed]
[21] 晚期肾透明细胞癌系统性治疗中国专家共识专家组, 中国临床肿瘤学会肾癌专家委员会, 中国抗癌协会泌尿系统肿瘤专业委员会. 晚期肾透明细胞癌系统性治疗中国专家共识(2024版) [J]. 中华肿瘤杂志, 2024, 46(9): 844-854.
[22] Hirose, T., Deguchi, S., Yasui, K., Inoue, M., Onoe, T., Ogawa, H., et al. (2024) The Indication of Palliative Whole-Brain Radiotherapy for Patients with Brain Metastases: A Simple Prognostic Scoring System in the Era of Stereotactic Radiosurgery. BMC Cancer, 24, Article No. 940. [Google Scholar] [CrossRef] [PubMed]
[23] Schiff, D., Messersmith, H., Brastianos, P.K., Brown, P.D., Burri, S., Dunn, I.F., et al. (2022) Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. Journal of Clinical Oncology, 40, 2271-2276. [Google Scholar] [CrossRef] [PubMed]